Cover Image

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

Background: Studies confirmed that trastuzumab plus fluorouracil-based chemotherapy improves the survival to more than 1 year in human with human epidermal growth factor receptor-2 (HER2)-positive advanced gastric cancer. However, there are still a small proportion of patients who do not benefit fro...

Full description

Saved in:

Bibliographic Details
Main Authors:	Huifang Lv (Author), Yunduan He (Author), Caiyun Nie (Author), Feng Du (Author), Xiaobing Chen (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
by: Kunlun Wang, et al.
Published: (2020)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
by: Caiyun Nie, et al.
Published: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi S, et al.
Published: (2014)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023)

Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
by: Wu Y, et al.
Published: (2023)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
by: Yun Yang, et al.
Published: (2018)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
by: SPH Mao, et al.
Published: (2023)

Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
by: Iago Dilion Lima Cavalcanti, et al.

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019)

The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature
by: Zhenpeng Wen, et al.
Published: (2024)

Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
by: Quan Liang, et al.
Published: (2016)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
by: Chen Y, et al.
Published: (2024)

Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC
by: Feifei Li, et al.
Published: (2024)

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
by: Yiwen You, et al.
Published: (2018)

Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells
by: Shaghayegh Saharkhiz, et al.
Published: (2024)

Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
by: Taha Koray Sahin, et al.
Published: (2024)

Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
by: Xiaofan Wu, et al.
Published: (2022)

Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis
by: Binlong Chen, et al.
Published: (2024)

Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
by: Zongyu Li, et al.
Published: (2023)

Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
by: Ratnakar Reddy Kuchukulla, et al.
Published: (2022)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021)

Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
by: Moslem Afrakhteh, et al.
Published: (2017)

Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients
by: Elena M. Tosca, et al.
Published: (2023)

Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
by: Sudewi Mukaromah Khoirunnisa, et al.
Published: (2023)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
by: Dingyi Jiang, et al.
Published: (2020)

Apatinib for molecular targeted therapy in tumor
by: Zhang H
Published: (2015)

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
by: Peter G. Rose
Published: (2023)

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier
by: Brandon M. Bordeau, et al.
Published: (2022)

Immune-Related Colitis Induced by Camrelizumab: A Case Report
by: Cheng S, et al.
Published: (2023)

In Vitro Assessment of <sup>177</sup>Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer
by: Ayça Tunçel, et al.
Published: (2024)

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA
by: Afsaneh Barzi, et al.
Published: (2023)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
by: Hao Lin, et al.
Published: (2023)

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
by: Christina Vasalou, et al.
Published: (2024)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022)

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients
by: Jia-qi Yuan, et al.
Published: (2020)